Marked response to single agent trastuzumab in a patient with metastatic HER-2 gene amplified rectal cancer

scientific article published on 22 June 2011

Marked response to single agent trastuzumab in a patient with metastatic HER-2 gene amplified rectal cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3109/07357907.2011.590569
P698PubMed publication ID21696295

P2093author name stringSteven M Sorscher
P433issue7
P921main subjecttrastuzumabQ412616
P304page(s)456-459
P577publication date2011-06-22
P1433published inCancer InvestigationQ325953
P1476titleMarked response to single agent trastuzumab in a patient with metastatic HER-2 gene amplified rectal cancer
P478volume29

Reverse relations

cites work (P2860)
Q34483980Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients
Q27027682Dual-labeling strategies for nuclear and fluorescence molecular imaging: a review and analysis
Q27853380Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Q35863066Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification
Q38694309FGFR2 Amplification in Colorectal Adenocarcinoma
Q35195738FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival
Q33979049HER-2 overexpression and survival in colorectal cancer: a meta-analysis
Q36843773Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.

Search more.